vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $8.6M, roughly 1.6× Affinity Bancshares, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 24.9%, a 50.8% gap on every dollar of revenue. Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-2.1M).
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
AFBI vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $13.7M |
| Net Profit | $2.1M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | 35.9% | -86.5% |
| Net Margin | 24.9% | 75.7% |
| Revenue YoY | 12.8% | — |
| Net Profit YoY | 58.5% | 179.1% |
| EPS (diluted) | $0.34 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $13.7M | ||
| Q3 25 | $8.4M | $19.1M | ||
| Q2 25 | $8.3M | $8.1M | ||
| Q1 25 | $7.8M | $2.9M | ||
| Q4 24 | $7.6M | — | ||
| Q3 24 | $8.0M | — | ||
| Q2 24 | $8.3M | — | ||
| Q1 24 | $7.3M | — |
| Q4 25 | $2.1M | $10.4M | ||
| Q3 25 | $2.2M | $-16.3M | ||
| Q2 25 | $2.2M | $-15.8M | ||
| Q1 25 | $1.8M | $-13.3M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | 35.9% | -86.5% | ||
| Q3 25 | 34.9% | -10.1% | ||
| Q2 25 | 34.1% | -177.7% | ||
| Q1 25 | 30.8% | -472.7% | ||
| Q4 24 | 21.1% | — | ||
| Q3 24 | 28.5% | — | ||
| Q2 24 | 16.2% | — | ||
| Q1 24 | 24.0% | — |
| Q4 25 | 24.9% | 75.7% | ||
| Q3 25 | 26.5% | -85.4% | ||
| Q2 25 | 25.9% | -196.0% | ||
| Q1 25 | 23.4% | -452.7% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | 21.7% | — | ||
| Q2 24 | 12.5% | — | ||
| Q1 24 | 18.2% | — |
| Q4 25 | $0.34 | $-3.74 | ||
| Q3 25 | $0.34 | $-0.11 | ||
| Q2 25 | $0.33 | $-0.16 | ||
| Q1 25 | $0.28 | $-0.18 | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $0.26 | — | ||
| Q2 24 | $0.16 | — | ||
| Q1 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $35.3M |
| Total Assets | $881.7M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $137.5M | ||
| Q3 25 | $84.8M | $103.8M | ||
| Q2 25 | $89.7M | $121.6M | ||
| Q1 25 | $74.7M | $89.1M | ||
| Q4 24 | $41.4M | — | ||
| Q3 24 | $52.3M | — | ||
| Q2 24 | $50.4M | — | ||
| Q1 24 | $61.4M | — |
| Q4 25 | $127.0M | $35.3M | ||
| Q3 25 | $125.4M | $-8.1M | ||
| Q2 25 | $124.1M | $7.1M | ||
| Q1 25 | $122.3M | $10.7M | ||
| Q4 24 | $129.1M | — | ||
| Q3 24 | $128.4M | — | ||
| Q2 24 | $125.1M | — | ||
| Q1 24 | $123.3M | — |
| Q4 25 | $881.7M | $154.7M | ||
| Q3 25 | $925.2M | $133.7M | ||
| Q2 25 | $933.8M | $133.8M | ||
| Q1 25 | $912.5M | $103.7M | ||
| Q4 24 | $866.8M | — | ||
| Q3 24 | $878.6M | — | ||
| Q2 24 | $873.6M | — | ||
| Q1 24 | $869.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-2.0M |
| Free Cash FlowOCF − Capex | $11.2M | $-2.1M |
| FCF MarginFCF / Revenue | 130.9% | -15.3% |
| Capex IntensityCapex / Revenue | 4.9% | 0.7% |
| Cash ConversionOCF / Net Profit | 5.46× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-2.0M | ||
| Q3 25 | $3.7M | $-17.5M | ||
| Q2 25 | $3.8M | $-14.5M | ||
| Q1 25 | $1.9M | $29.0M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $619.0K | — | ||
| Q1 24 | $1.2M | — |
| Q4 25 | $11.2M | $-2.1M | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.7M | $-14.9M | ||
| Q1 25 | $1.8M | $29.0M | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $489.0K | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | 130.9% | -15.3% | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | -184.0% | ||
| Q1 25 | 22.7% | 988.3% | ||
| Q4 24 | 83.9% | — | ||
| Q3 24 | 49.5% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 4.9% | 0.7% | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 1.4% | 5.0% | ||
| Q1 25 | 1.9% | 0.8% | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 5.46× | -0.19× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
